Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
Go back to Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases| RITE AID CORPORATION (NYSE: RAD) | Delayed: 0.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $8.30 | |||
| Open | $11.16 | 52 Week Low | $6.33 | |||
| Day High | $0.65 | P/E | 1.91 | |||
| Day Low | $0.65 | EPS | $0.34 | |||
| Volume | 63,391 | |||||
| (NASDAQ: RADX) | Delayed: 2.12 +0.04 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.08 | 52 Week High | $ | |||
| Open | $2.08 | 52 Week Low | $ | |||
| Day High | $2.30 | P/E | N/A | |||
| Day Low | $2.06 | EPS | $ | |||
| Volume | 27,663 | |||||
